Carnegie Capital Asset Management, LLC Anavex Life Sciences Corp. Transaction History
Carnegie Capital Asset Management, LLC
- $3.18 Billion
- Q2 2024
A detailed history of Carnegie Capital Asset Management, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Carnegie Capital Asset Management, LLC holds 73,333 shares of AVXL stock, worth $398,931. This represents 0.01% of its overall portfolio holdings.
Number of Shares
73,333
Previous 73,333
-0.0%
Holding current value
$398,931
Previous $373,000
17.16%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding AVXL
# of Institutions
152Shares Held
26.5MCall Options Held
674KPut Options Held
811K-
Black Rock Inc. New York, NY6.39MShares$34.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.55MShares$24.7 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$20.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.83MShares$9.96 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY1.01MShares$5.51 Million0.01% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $424M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...